Boehringer Ingelheim Venture Fund
Overview
The Boehringer Ingelheim Venture Fund (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research . BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs . BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| smartbax GmbH | Jun 2026 | Early Funding | Co-investor |
| Tacalyx | Apr 2026 | Seed | Co-investor |
| TECregen | Jan 2026 | Seed | Lead |
| STRM.BIO | Jan 2026 | Series 2 | Co-investor |
| STRM.BIO | Dec 2025 | Grant | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
